Compare · NSPR vs PEN
NSPR vs PEN
Side-by-side comparison of InspireMD Inc. (NSPR) and Penumbra Inc. (PEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NSPR and PEN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- PEN is the larger of the two at $12.64B, about 353.2x NSPR ($35.8M).
- NSPR has been more active in the news (9 items in the past 4 weeks vs 5 for PEN).
- PEN has more recent analyst coverage (25 ratings vs 1 for NSPR).
- Company
- InspireMD Inc.
- Penumbra Inc.
- Price
- -
- -
- Market cap
- $35.8M
- $12.64B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 9
- 5
- Recent ratings
- 1
- 25
InspireMD Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.
Penumbra Inc.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Latest NSPR
- InspireMD Announces Pricing of $37.5 Million Public Offering
- SEC Form 424B5 filed by InspireMD Inc.
- InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- InspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- InspireMD Announces Proposed Public Offering
- InspireMD Reports Third Quarter 2026 Financial Results
- InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures
- InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results
- InspireMD to Announce Third Quarter 2026 Financial Results
- SEC Form 4 filed by Director Roubin Gary S
Latest PEN
- Amendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.
- SEC Form 10-Q filed by Penumbra Inc.
- SEC Form 8-K filed by Penumbra Inc.
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
- SEC Form 4 filed by Penumbra Inc.
- New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
- President Narayan Shruthi covered exercise/tax liability with 1,230 shares, decreasing direct ownership by 4% to 32,650 units (SEC Form 4) to satisfy withholding obligation
- President Narayan Shruthi was granted 3,060 shares, increasing direct ownership by 10% to 33,880 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Penumbra Inc.